Mercer Global Advisors
ACRS icon

Mercer Global Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Mercer Global Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.7K Buy
10,595
+428
+4% +$1.44K ﹤0.01% 3147
2025
Q4 		$30.6K Sell
10,167
-293
-3% -$740 ﹤0.01% 2812
2025
Q3 		$19.9K Buy
10,460
+240
+2% +$418 ﹤0.01% 2619
2025
Q2 		$14.5K Hold
10,220
– – ﹤0.01% 2232
2025
Q1 		$15.6K Buy
+10,220
New +$21.8K ﹤0.01% 2132

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Mercer Global Advisors's ACRS Position: Q1 2026 in Review

Mercer Global Advisors increased its Aclaris Therapeutics (ACRS) stake by 4.2% in Q1 2026, buying an estimated $1.44K and bringing the position to 10,595 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3147.

Mercer Global Advisors first reported a position in ACRS in Q1 2025 and has held it in 5 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Mercer Global Advisors held 10,595 shares of Aclaris Therapeutics worth $39.7K as of Q1 2026.
  • Mercer Global Advisors bought 428 Aclaris Therapeutics shares in Q1 2026, an estimated $1.44K.
  • Aclaris Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3147 holding.
  • Mercer Global Advisors first reported a position in Aclaris Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.